Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Exelixis
With that in mind, let's take a closer look at Exelixis' business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||San Francisco (1994)|
|Market Cap||$738.5 million|
|Trailing-12-Month Revenue||$289.6 million|
|Management||Co-Founder/Chairman Dr. Stelios Papadopoulos
President/CEO Dr. Michael Morrissey
|Trailing-12-Month Return on Capital||49.4%|
|Cash/Debt||$194.3 million / $181.5 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 2,597 members who have rated Exelixis believe the stock will outperform the S&P 500 going forward.
It's cancer fighting drug cabozantinib is still undergoing phase 3 trials, but things are look pretty promising to me at this point. It also offers the unique benefit of pain reduction, which could help distinguish it from other competing drugs.
If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its four-star rating, Exelixis may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Exelixis. Motley Fool newsletter services have recommended buying shares of Novartis and Exelixis. The Motley Fool has a disclosure policy.